BCAL DiagnosticsASX:BDX -3.70% Pretax Margin % is -9,060.47% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 98.51% on this metric.
The historical rank and industry rank for BCAL Diagnostics's Pretax Margin % or its related term are showing as below:
ASX:BDX'
s Pretax Margin % Range Over the Past 10 Years
Min: -32913.64 Med: -32913.64 Max: -16600
Current: -16600
ASX:BDX's Pretax Margin % is ranked worse than 98.51% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs ASX:BDX: -16600.00
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
BCAL Diagnostics Pretax Margin % Related Terms
BCAL Diagnostics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BDX vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, BCAL Diagnostics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a Pretax Margin % of -9,060.47% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #199 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 98.5%.
Is BCAL Diagnostics' Pretax Margin % too high?
BCAL Diagnostics' current Pretax Margin % is -9,060.47%. Based on the distribution chart, BCAL Diagnostics ranks #199 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #199 out of 202 companies for Pretax Margin %. This places BCAL Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Pretax Margin % is -9,060.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Pretax Margin % of -9,060.47%. The current Pretax Margin % is -9,060.47%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Pretax Margin % is -9,060.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 